


Ibiglustat L-Malic acid

Chemical Properties

| | |
|-------------------|--|
| CAS No.: | 1629063-78-0 |
| Formula: | C ₂₄ H ₃₀ FN ₃ O ₇ S |
| Molecular Weight: | 523.57 |
| Appearance: | N/A |
| Storage: | 0-4°C for short term (days to weeks), or -20°C for long term (months). |



Biological Description

| | |
|----------------------------|---|
| Description | Ibiglustat L-Malic acid (Venglustat L-Malic acid) is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with the ability to cross the blood-brain barrier. It can be used for the research of PD Parkinson' s disease, SRT in Fabry' s and Gaucher' s. |
| Targets(IC ₅₀) | Glucosylceramide synthase: None |
| In vitro | Ibiglustat (1 μM, 15 days) treated FD cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes [4]. |

Solubility Information

| | |
|------------|---|
| Solubility | DMSO: 100 mg/mL (191.00 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|----------|----------|----------|
| 1 mM | 1.91 mL | 9.55 mL | 19.1 mL |
| 5 mM | 0.382 mL | 1.91 mL | 3.82 mL |
| 10 mM | 0.191 mL | 0.955 mL | 1.91 mL |
| 50 mM | 0.038 mL | 0.191 mL | 0.382 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. WO 2015089067 A1.
2. Iva Stojkowska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson' s disease. Cell Tissue Res. 2017.
3. Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 1687–1700.
4. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481